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Seborrheic dermatitis in COVID-19: a case report
Dear Editor,
This report analyzes the case of a 63-year-old Caucasian
male, Fitzpatrick III phototype, who was admitted to the Inten-
sive Care Unit (ICU) due to a severe coronavirus disease 2019
(COVID-19) pneumonia. The patient’s medical history was
remarkable for valvular heart disease, the presence of a biologi-
cal aortic valve, and primary arterial hypertension, but he had
no prior history of any dermatological complaints. The patient
was chronically medicated with furosemide 40mg bid, apixaban
5mg bid, and amlodipine 5mg od. At admission, laboratory stud-
ies revealed mild lymphopenia (900/µL). Lopinavir/ritonavir and
hydroxychloroquine were administered for 14 days. He was
ventilated at admission for 21 days until his respiratory function
improved.
At day 33, the patient developed a nonpruriginous erythe-
matosquamous dermatosis localized in the face, affecting the
forehead, supraciliary regions, and nasolabial folds, with out-
ward extension to both cheeks (Fig. 1). The scale was coarse
and adherent. The patient denied any previous episodes, and
no other changes were detected on dermatological examination.
Seborrheic dermatitis (SD) was diagnosed, and the patient was
prescribed hydrocortisone cream bid, with complete resolution
of the dermatosis after 7 days.
Several dermatological manifestations of COVID-19 have
been described,1 but no reports of SD in COVID-19 have been
published so far. At our center, we have seen several cases of
SD in patients admitted to the ICU due to COVID-19; the asso-
ciation between the two diseases may not be incidental. While
the pathophysiology of SD is not consensual, cellular immunity,
inflammatory cytokines, and neurogenic factors have been
implicated in its pathogenesis.
Severe COVID-19 may be seen with lymphopenia which in
turn may be a contributing factor to SD onset, similar to individ-
uals with the human immunodeficiency virus (HIV) infection,
and particularly those with CD4 + counts in the 200-500/µL
range, show increased incidence and severity of SD.2 The
onset of a severe form of SD is often the sign which leads to
the diagnosis of HIV.
Increased production of inflammatory cytokines may also
link COVID-19 to SD. It is now accepted that the most severe
forms of COVID-19 are caused by a “cytokine storm” and not
by a direct cytopathic effect of the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2). This proinflammatory sta-
tus features high levels of circulating cytokines such as
Interleukin-1, Interleukin-6, and tumor necrosis factor alpha
(TNF-a). These cytokines have been shown to be present at
higher concentration in SD-affected skin than in healthy skin.3
An immune reconstitution syndrome in HIV infection under
antiretroviral treatment is also positively associated with SD; this
supports the role of an inflammatory response to the pathogen-
esis of this dermatosis.
The third link between the two conditions is neurogenic
mechanisms. SARS-CoV-2 shows neurotropism, and neurologi-
cal manifestations of COVID-19 have been described.4 Con-
comitantly, the role of neurogenic factors in relation to SD has
been mentioned since patients with neurodegenerative condi-
tions, such as Alzheimer’s disease or Parkinson’s disease, have
increased incidence of SD. The report of significant improve-
ment of SD after stellate ganglion block, which may relate to a
Figure 1 Erythematosquamous dermatosis with thick adherent
scale, affecting the forehead, supraciliary regions, and nasolabial
folds, with outward extension to both cheeks. These findings are
characteristic of seborrheic dermatitis
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decrease in Interleukin-6 production, provides further support to
this hypothesis.5
SD and COVID-19 may share common mechanisms, which
could explain cases such as the one in this report. Awareness
about this dermatosis is necessary to prevent a misdiagnosis of
contact dermatitis to either medical devices or personal protec-
tive equipment. When assessing patients with de novo onset of
severe SD, or significant exacerbation of a previously mild SD,
physicians should consider the possibility of underlying COVID-
19 as they do for HIV infection. Such cases require a thorough
anamnesis and epidemiological survey, rather than preemptive
testing in all cases, as other factors may lead to the onset or
aggravation of SD (e.g., prolonged use of PPE).
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